Lili Mao - Concepedia

Author

Lili Mao

Peking University Cancer Hospital ORCID

Also Known As

L L Mao, L. Mao, Li-Li Mao, Li-li Mao, LiLi Mao, Lili Mao

234

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

Peking University Cancer Hospital Peking University Ministry of Education Sun Yat-sen University Cancer Center Sun Yat-sen University

About

Lili Mao is an author at Peking University Cancer Hospital specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	21	639
2	Public Health	2	2	90
3	Engineering	1	1	21
4	Health Sciences	1	1	12
5	Natural Sciences	1	1	20

Lili Mao

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring <i>c-Kit</i> Mutation or Amplification Jun Guo, Lu Si, Yan Kong, Journal of Clinical Oncology	2011	673
Large-Scale Analysis of <i>KIT</i> Aberrations in Chinese Patients with Melanoma Yan Kong, Lu Si, Yanyan Zhu, Clinical Cancer Research	2011	251
The Placental Microbiome Varies in Association with Low Birth Weight in Full-Term Neonates Jia Zheng, Xinhua Xiao, Qian Zhang, Nutrients	2015	194
Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma Bin Lian, Lu Si, Chuanliang Cui, Clinical Cancer Research	2013	193
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients Bixia Tang, Xieqiao Yan, Xinan Sheng, Journal of Hematology & Oncology	2019	185
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G<sub>4</sub> Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial Xinan Sheng, Xieqiao Yan, Zhihong Chi, Journal of Clinical Oncology	2019	165
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151) Lu Si, Xiaoshi Zhang, Yongqian Shu, Translational Oncology	2019	133
Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy Yan Kong, Xinan Sheng, Xiaowen Wu, Clinical Cancer Research	2017	115
<i>MAPK</i> Pathway and <i>TERT</i> Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases Xue Bai, Yan Kong, Zhihong Chi, Clinical Cancer Research	2017	112
Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma Jiayi Yu, Junya Yan, Qian Guo, Clinical Cancer Research	2019	107

Page 1